AC 0939
Alternative Names: AC-0939; STI-8591Latest Information Update: 11 Aug 2026
At a glance
- Originator ACEA Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Tropomyosin-related kinase antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- Discontinued Liver cancer
Most Recent Events
- 11 Aug 2026 Discontinued - Preclinical for Liver cancer in China (unspecified route) (Vivasor Pipeline, August 2026)
- 02 Feb 2024 Preclinical trials in Liver cancer in China (unspecified route), prior to February 2024 (ACEA Therapeutics pipeline, February 2024)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition